BR112018015893A2 - vacinas de câncer e métodos de tratamento usando as mesmas - Google Patents
vacinas de câncer e métodos de tratamento usando as mesmasInfo
- Publication number
- BR112018015893A2 BR112018015893A2 BR112018015893A BR112018015893A BR112018015893A2 BR 112018015893 A2 BR112018015893 A2 BR 112018015893A2 BR 112018015893 A BR112018015893 A BR 112018015893A BR 112018015893 A BR112018015893 A BR 112018015893A BR 112018015893 A2 BR112018015893 A2 BR 112018015893A2
- Authority
- BR
- Brazil
- Prior art keywords
- same
- treatment methods
- cancer vaccines
- vaccine
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 238000009566 cancer vaccine Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 2
- 101000655350 Canis lupus familiaris Telomerase reverse transcriptase Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
a presente invenção refere-se a uma vacina compreendendo uma molécula de ácido nucleico que codifica um antígeno da transcriptase reversa da telomerase do cão (dtert), bem como métodos de uso da vacina para induzir uma resposta imune contra uma tert e para tratar câncer em um mamífero.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662291601P | 2016-02-05 | 2016-02-05 | |
PCT/US2017/016557 WO2017136758A1 (en) | 2016-02-05 | 2017-02-03 | Cancer vaccines and methods of treatment using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018015893A2 true BR112018015893A2 (pt) | 2019-03-06 |
Family
ID=59500919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018015893A BR112018015893A2 (pt) | 2016-02-05 | 2017-02-03 | vacinas de câncer e métodos de tratamento usando as mesmas |
Country Status (10)
Country | Link |
---|---|
US (3) | US11007255B2 (pt) |
EP (1) | EP3411122A4 (pt) |
JP (1) | JP7123800B2 (pt) |
KR (1) | KR20180108793A (pt) |
CN (1) | CN108883312B (pt) |
AU (2) | AU2017214656B2 (pt) |
BR (1) | BR112018015893A2 (pt) |
CA (1) | CA3013718C (pt) |
MX (2) | MX2018009506A (pt) |
WO (1) | WO2017136758A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018217982A1 (en) * | 2017-05-26 | 2018-11-29 | The Wistar Institute Of Anatomy And Biology | Dtert vaccines and methods of treatment using the same |
CN111511392A (zh) | 2017-10-31 | 2020-08-07 | 潘塔希生物科学股份有限公司 | 用于治疗和/或预防肺癌的免疫治疗方法 |
WO2021259963A1 (en) | 2020-06-23 | 2021-12-30 | Pandora Endocrine Innovation B.V. | Immunization against wnt4 for treatment and prophylaxis of breast cancer |
WO2023066923A1 (en) | 2021-10-19 | 2023-04-27 | Rahman Nafis | Male contraception |
WO2023237726A1 (en) | 2022-06-10 | 2023-12-14 | Pantarhei Oncology B.V. | An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
NZ262582A (en) | 1993-01-26 | 1997-10-24 | David B Weiner | Compositions and methods for delivery of genetic material |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
NL9401820A (nl) | 1994-11-02 | 1996-06-03 | Meyn Maschf | Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte. |
US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
JP2001520537A (ja) | 1997-04-03 | 2001-10-30 | エレクトロフェクト・アクティーゼルスカブ | 医薬品と核酸の骨格筋への導入方法 |
HUP0004589A3 (en) | 1997-06-30 | 2003-08-28 | Centre Nat Rech Scient | Improved method for transferring nucleic acid into the striped muscle and combination therefor |
EP1100579B1 (en) | 1998-07-13 | 2015-09-02 | Inovio Pharmaceuticals, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
US20040175727A1 (en) | 2002-11-04 | 2004-09-09 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
CA2567324C (en) | 2003-05-30 | 2012-01-03 | Advisys, Inc. | Devices and methods for biomaterial production |
CN105132439A (zh) | 2006-07-28 | 2015-12-09 | 宾夕法尼亚大学托管会 | 改进的疫苗及其使用方法 |
MX2009003873A (es) * | 2006-10-12 | 2009-04-22 | Angeletti P Ist Richerche Bio | Proteina de fusion de transcriptasa inversa de telomerasa, nucleotidos que la codifican y usos de la misma. |
EP2066399B1 (en) | 2006-10-17 | 2018-10-03 | Inovio Pharmaceuticals, Inc. | Electroporation devices and methods of using same for electroporation of cells in mammals |
PT2153260T (pt) | 2007-05-23 | 2017-04-24 | Vgxi Inc | Composição que compreende uma alta concentração de moléculas biologicamente ativas e processos de preparação da mesma |
US20140236070A1 (en) * | 2011-07-29 | 2014-08-21 | Kate Broderick | Linear expression cassettes and uses thereof |
US11419925B2 (en) | 2013-03-15 | 2022-08-23 | The Trustees Of The University Of Pennsylvania | Cancer vaccines and methods of treatment using the same |
JP6479761B2 (ja) * | 2013-03-28 | 2019-03-06 | アンヴェクティInvectys | イヌ用がんワクチン |
WO2015023461A2 (en) * | 2013-08-06 | 2015-02-19 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
WO2018217982A1 (en) * | 2017-05-26 | 2018-11-29 | The Wistar Institute Of Anatomy And Biology | Dtert vaccines and methods of treatment using the same |
-
2017
- 2017-02-03 WO PCT/US2017/016557 patent/WO2017136758A1/en active Application Filing
- 2017-02-03 BR BR112018015893A patent/BR112018015893A2/pt active Search and Examination
- 2017-02-03 AU AU2017214656A patent/AU2017214656B2/en active Active
- 2017-02-03 EP EP17748295.7A patent/EP3411122A4/en active Pending
- 2017-02-03 CA CA3013718A patent/CA3013718C/en active Active
- 2017-02-03 CN CN201780020641.5A patent/CN108883312B/zh active Active
- 2017-02-03 MX MX2018009506A patent/MX2018009506A/es unknown
- 2017-02-03 JP JP2018540794A patent/JP7123800B2/ja active Active
- 2017-02-03 US US16/075,527 patent/US11007255B2/en active Active
- 2017-02-03 KR KR1020187025572A patent/KR20180108793A/ko active Search and Examination
-
2018
- 2018-08-03 MX MX2023001540A patent/MX2023001540A/es unknown
-
2021
- 2021-04-09 US US17/226,633 patent/US11801288B2/en active Active
-
2022
- 2022-11-17 AU AU2022271441A patent/AU2022271441A1/en active Pending
-
2023
- 2023-09-22 US US18/472,640 patent/US20240082374A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2023001540A (es) | 2023-03-08 |
EP3411122A4 (en) | 2019-10-23 |
CN108883312A (zh) | 2018-11-23 |
JP7123800B2 (ja) | 2022-08-23 |
AU2017214656A1 (en) | 2018-08-30 |
US20240082374A1 (en) | 2024-03-14 |
CA3013718C (en) | 2023-09-26 |
US11007255B2 (en) | 2021-05-18 |
KR20180108793A (ko) | 2018-10-04 |
CA3013718A1 (en) | 2017-08-10 |
AU2022271441A1 (en) | 2022-12-22 |
US20210268084A1 (en) | 2021-09-02 |
WO2017136758A1 (en) | 2017-08-10 |
US11801288B2 (en) | 2023-10-31 |
AU2017214656B2 (en) | 2022-08-25 |
JP2019508403A (ja) | 2019-03-28 |
MX2018009506A (es) | 2019-05-06 |
EP3411122A1 (en) | 2018-12-12 |
CN108883312B (zh) | 2024-04-09 |
US20190038729A1 (en) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123563T1 (el) | Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων | |
BR112018015893A2 (pt) | vacinas de câncer e métodos de tratamento usando as mesmas | |
BR112016010166A2 (pt) | métodos para usar interleucina-10 para tratar doenças e distúrbios | |
CO2017006580A2 (es) | Anticuerpos humanos para hemaglutinina de influenza | |
BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
BR112018008090A2 (pt) | vacina de vírus do herpes simplex. | |
BR112017000703A2 (pt) | métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit | |
CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
MX2022007522A (es) | Anticuerpos anti-cd27. | |
BR112017001310A2 (pt) | coronavírus | |
BR112017008696A2 (pt) | métodos e composições para células exterminadoras naturais | |
BR112018008577A2 (pt) | anticorpos que neutralizam o vírus sincicial respiratório humano | |
CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
UY35716A (es) | Proteínas de unión al antígeno gitr | |
BR112016010716A8 (pt) | dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina | |
UY35682A (es) | Anticuerpos anti-activina a y usos de los mismos | |
MX2017005325A (es) | Enfoque de inmunoterapias de combinación para el tratamiento del cancer. | |
CL2016002794A1 (es) | Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico | |
CL2015001900A1 (es) | Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina. | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
CL2016000538A1 (es) | Compuesto que comprende la proteína globo h y klh, composiciones de una vacuna de hidratos de carbono para la inducción de respuestas inmunes y usos de los mismos | |
BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
MX2018001755A (es) | Vacuna contra viruela para tratamiento del cancer. | |
BR112015023524A2 (pt) | vacinas poxvirais melhoradas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |